Financial Tear Sheet


Tempest and Millendo have announced a merger.


Financial Tear Sheet

Corporate Profile

Millendo Therapeutics is a biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases. We create distinct and transformative treatments for endocrine diseases where there is a significant unmet medical need.  

Primary IR Contact

Investor inquiries should be directed to or 734-845-9000.

Stock Quote

Price Change
Volume % Change  
Intraday High 52 Week High
Intraday Low 52 Week Low
Today's Open Currency US Dollar
Previous Close Exchange

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart